PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Negative revenue growth while Biotechnology median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-116.81%
Negative gross profit growth while Biotechnology median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-52.01%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-52.01%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-52.47%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-43.48%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-43.48%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
7.17%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
7.17%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
582.93%
OCF growth of 582.93% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
577.68%
FCF growth of 577.68% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
OCF/share CAGR of 9508.05% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
131.96%
OCF/share CAGR of 131.96% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
210.81%
3Y OCF/share growth of 210.81% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
88.12%
Net income/share CAGR of 88.12% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
91.00%
Net income/share CAGR of 91.00% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
67.11%
3Y net income/share CAGR of 67.11% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1963.85%
Equity/share CAGR of 1963.85% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-27.97%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
5.99%
3Y equity/share CAGR of 5.99% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
We expand assets while Biotechnology is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
5.97%
Positive BV/share change while Biotechnology median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
1244.16%
Debt growth of 1244.16% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
6.71%
R&D growth of 6.71% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
86.34%
SG&A growth of 86.34% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.